-
Exiled Russian dissident Navalnaya warns dictators becoming 'more cunning'
-
Africa Ebola outbreak passes 10,000 cases, mostly in DR Congo
-
Bayern 'risk' reaps huge reward for Ballon d'Or winner Kane
-
EU pushes for more nations to pay to protect nature
-
Record turnout as Israeli voters deliver verdict on Netanyahu
-
Boeing reports smaller loss as it aims for stable output growth
-
Iraola says Isak 'feels the trust' after Liverpool scoring streak
-
Tech firms gain on Anthropic IPO optimism; HSBC slumps in London
-
French media protest manhandling of journalists at far-right party rally
-
Sri Lanka end England hopes with crushing win over Pakistan
-
EU seeks deportation powers for beefed up border agency
-
Dangote, Nigeria's oil tycoon rewriting Africa's story
-
Two charged with UK security offences over airbase plot: police
-
Carrick to remain Man Utd boss for Chelsea clash: reports
-
Maresca defends Donnarumma, Guehi after Man City defeat
-
Greenhouse gas levels hit new record highs in 2025: UN
-
Nordic leaders call Putin as local truce begins in Ukraine
-
Rybakina looking to clinch year-end number one in Tokyo
-
Osaka unveils crane outfit in Tokyo before win over Paolini
-
Tech firms track Wall St rally on mixed day for stock markets
-
Ronaldo in line for Portugal return after fallout with coach
-
Kane says Ballon d'Or win 'feels like a dream' as tributes pour in
-
Norway media take legal action to block Meta from using content
-
HSBC profit jumps on higher rates, lower costs
-
Bayern praise 'humble' Kane after Ballon d'Or win
-
Rams rediscover offensive balance in 35-21 victory over Raiders
-
Colts retain Daniel Jones as starter despite continued offensive struggles
-
Mercedes-Benz cuts 2026 profit outlook on tough China market
-
Madushanka wrecks Pakistan as Sri Lanka press for final slot
-
Reparations calls follow Charles on tough Caribbean trip
-
Destructive Abhishek 113 leads India to series win over New Zealand
-
Jammu and Kashmir ministers resign before planned council expansion
-
Norway, Finland leaders hold 'frank and substantive' talk with Putin
-
Germany, EU, stable investment stops despite upheaval: Merz
-
Wall Street faces earnings and Fed tests after turbulent technology-led week
-
China brands drop Mbappe for 'offending national sentiments'
-
Ukraine, Russia say US-brokered truce holding in ravaged city
-
India orders evacuations as Cyclone Arnab looms
-
Police form SIT after vehicles in Rahul Gandhi convoy collide on expressway
-
Dutch broadcaster pulls out of Eurovision over Israel 'sensitivities'
-
Delhi grants minimum monthly pay and DA to about 4,000 MCD health workers
-
Critical coal inventories affect nearly half of India’s domestic power plants
-
Ather Energy shares climb 14% after quarterly profit and expansion plan
-
FCNR(B) deposit drive puts sharper margin pressure on private banks
-
Gold ETF flows turn negative after 13 weeks as bullion loses 4%
-
Noel Tata requests records of September 17 Tata Sons board meeting
-
Pakistan's last antique restorers give old treasures new life
-
Reparations calls to dog King Charles's tough Caribbean trip
-
India braces for Cyclone Arnab with evacuations
-
Global rates and foreign outflows remain key risks for Indian markets
Lantern Pharma Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FLORIDA / ACCESS Newswire / July 25, 2025 / RedChip Companies will air an interview with Lantern Pharma Inc. (Nasdaq:LTRN) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 26, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Access the interview in its entirety at: https://www.redchip.com/assets/access/ltrn_access
In an exclusive interview, Panna Sharma, CEO of Lantern Pharma, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss how Lantern is redefining oncology drug development through its proprietary AI platform, RADR®. Sharma highlights Lantern's clinical-stage programs (LP-300, LP-184, and LP-284) which address high-need indications such as NSCLC in never-smokers, DDR-deficient solid tumors, and aggressive lymphomas. He also shares how Lantern's capital-efficient AI-driven model, which has enabled 12 oncology programs in just two years at a fraction of traditional development costs, is driving rapid value creation. With multiple upcoming clinical readouts, an expanding AI-driven pipeline, and over 100 issued and pending patents, Lantern is positioned as a next-generation biotech innovator at the intersection of artificial intelligence and precision oncology.
LTRN is a client of RedChip Companies. Please read our full disclosure at https://www.redchip.com/legal/disclosures.
About Lantern Pharma
Lantern Pharma (NASDAQ:LTRN) is an AI-driven biotechnology company focused on accelerating and optimizing the discovery, development, and commercialization of cancer therapies. Its RADR® platform leverages artificial intelligence and machine learning to uncover novel therapeutic opportunities, accelerate drug development, and improve patient outcomes.
Please find more information at:
Website: www.lanternpharma.com
About RedChip Companies
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 33 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. RedChip also offers RedChat™, a proprietary AI-powered chatbot that analyzes SEC filings and corporate disclosures for all Nasdaq and NYSE-listed companies, giving investors instant, on-demand insights.
To learn more about RedChip's products and services, please visit:
https://www.redchip.com/corporate/investor_relations
"Discovering Tomorrow's Blue Chips Today"™
Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/
Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies
Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/
Follow RedChip on Twitter: https://twitter.com/RedChip
Follow RedChip on YouTube: https://www.youtube.com/@redchip
Follow RedChip on Rumble: https://rumble.com/c/c-3068340
Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest
Contact:
Dave Gentry
RedChip Companies Inc.
1-407-644-4256
[email protected]
--END--
SOURCE: RedChip Companies, Inc. (Media Suite)
View the original press release on ACCESS Newswire
H.Romero--AT